Gilead Sciences, Inc.

While significant progress has been made in the treatment of non-small cell lung cancer (NSCLC), small-cell lung cancer (SCLC) has seen fewer advances and patients continue to have limited treatment o

Therapies ranging from small molecules to immuno-oncology drugs will make appearances at the 2025 American Society of Clinical Oncology meeting. These include drugs that are seen as having the potenti

With new data presented at the recent European Association for the Study of the Liver meeting, Gilead is ready to seek US approval of its hepatitis D therapy bulevirtide once again. The firm had been

At SynBioBeta 2025, In Vivo spoke with several executives leading companies at the cutting edge of synthetic biology and techbio. These conversations revealed not just technological breakthroughs, b